The role of conventional radiotherapy in the management of pancreatic cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy (SBRT) has emerged as a novel therapeutic option in pancreatic cancer care. This study evaluated the survival impact of SBRT on patients with unresected pancreatic cancer. METHODS: The National Cancer Data Base was queried for unresected patients who received chemotherapy for nonmetastatic pancreatic adenocarcinoma between 2004 and 2012. Four treatment groups were identified: chemotherapy alone, chemotherapy combined with external-beam radiotherapy (EBRT), chemotherapy combined with intensity-modulated radiotherapy (IMRT), and chemotherapy combined with SBRT. Propensity score models predicting the odds of receiving SBRT were created to control for potential selection bias, and patients were matched by propensity scores. The survival analysis was performed with the Kaplan-Meier method. RESULTS: A total of 14,331 patients met the inclusion criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy along with EBRT, IMRT, and SBRT, respectively. The unadjusted median survival before matching was 9.9, 10.9, 12.0, and 13.9 months for patients treated with chemotherapy, EBRT, IMRT, and SBRT, respectively. In separate matched analyses, SBRT remained superior to chemotherapy alone (log-rank P < .0001) and EBRT (log-rank P 5 .0180). After matching, survival did not differ between patients receiving IMRT and patients receiving SBRT (log-rank P 5 .0492). CONCLUSIONS: SBRT is associated with a significantly better outcome than chemotherapy alone or in conjunction with traditional EBRT. These results support the idea that SBRT is a promising treatment approach for patients with unresected pancreatic cancer. Cancer 2017;123:4158-67.
INTRODUCTION
Pancreatic cancer currently ranks as the third leading cause of cancer death and is estimated to become the second leading cause by 2020. 1, 2 Despite continued advancements in treatment modalities, the 5-year survival rate remains less than 8%. 1 Complete surgical resection provides the only hope for long-term survival. Unfortunately, 80% to 85% of patients are diagnosed with unresectable disease because of distant metastases or locally advanced tumors. 3 Chemotherapy, often combined with traditional fractionated external-beam radiotherapy (EBRT), is considered the standard of care for unresectable pancreatic cancer patients throughout the United States. 4 However, studies assessing outcomes after radiation therapy have demonstrated conflicting results. 5, 6 Traditionally, radiotherapy consisted of EBRT; however, randomized controlled trials investigating EBRT have shown conflicting results. [5] [6] [7] [8] [9] These findings may in part be explained by the intrinsic radio resistance of pancreatic cancer cells. 10, 11 Stereotactic body radiotherapy (SBRT) permits the precise application of high-dose radiation in 1 to 5 fractions to a limited target volume and, therefore, offers a potential advantage in pancreatic cancer because of its ablative dosing to overcome the radio resistance. 12 Moreover, the accuracy and swift dose falloff of SBRT may reduce the radiation dose to adjacent healthy tissue and subsequently minimize toxicity. In addition, SBRT can be concluded in 1 to 2 days in contrast to the 4 or more weeks that it takes to complete EBRT, and this prevents a delay in the administration of chemotherapy. 13 Furthermore, the majority of emerging data on SBRT have demonstrated promising rates of local control ranging from 49% to 100%. 14 Various single-and multi-institution studies have already shown encouraging outcomes for SBRT. 13, 14 However, to the best of our knowledge, the outcomes of SBRT have never been compared with the outcomes of conventional treatment approaches for patients with unresected pancreatic cancer. Using population data, the current study investigates the survival impact of chemotherapy plus SBRT versus chemotherapy alone and chemotherapy combined with EBRT or intensity-modulated radiotherapy (IMRT).
MATERIALS AND METHODS

Database
The National Cancer Data Base (NCDB) is a collective venture of the American College of Surgeons and the American Cancer Society. This nationwide database includes oncologic outcomes for more than 1500 Commission on Cancer-accredited programs. Accordingly, the NCDB captures roughly 70% of all newly diagnosed cases of cancer in the United States. Furthermore, the NCDB requires centers to maintain a 90% follow-up rate for patients diagnosed within 5 years to remain accredited. 15 All NCDB data are de-identified, and hence this study was exempt from institutional review board review.
Patient Selection
This retrospective study queried the NCDB for patients with pancreatic adenocarcinoma (n 5 204,387) diagnosed between 2004 and 2012. Pancreatic adenocarcinoma was defined according to International Classification of Diseases for Oncology, 3rd edition (ICD-O-3), morphology codes for adenocarcinoma (8140 and 8500) in combination with the following ICD-O-3 topography codes: C25.0, C25.1, C25.2, C25.3, C25.7, C25.8, and C25.9. 16 For the purpose of this study, the terms pancreatic cancer and pancreatic adenocarcinoma are used interchangeably.
Patients with metastatic disease at diagnosis (n 5 85,653) or surgery of the primary site (n 5 42,794) were excluded. Patients who underwent resection were identified according to the Facility Oncology Registry Data Standards surgery codes: 25, 30, 35, 36, 37, 40, 60, 70, 80 , and 90. The cohort was further restricted by the sequential exclusion of patients who did not receive any treatment at the reporting facility (n 5 13,659), were diagnosed with other malignancies (n 5 11,501), or did not receive chemotherapy (n 5 22,417) as well as those whose radiation treatment included electrons and/or neutrons (n 5 54), proton therapy (n 5 43), or radioisotopes (n 5 11) or who started treatment more than 90 days after their diagnosis (n 5 1222). In addition, patients who died or were last contacted within the 3 months after their diagnosis (n 5 2421) were excluded to correct for a potential immortality bias. 17 Furthermore, patients for whom at least 1 of the following variables was missing or unknown were excluded sequentially: vital status (n 5 3049); age, sex, or race (n 5 259); comorbidities, other malignancies, or insurance status (n 5 750); facility type or integrated network cancer programs (n 5 1513); tumor location or clinical stage (n 5 3061); surgery of the primary site (n 5 47); receipt of chemotherapy (n 5 787); receipt of radiotherapy (n 5 152); and number of days from diagnosis to treatment greater than 90 (n 5 663).
Construction of Variables
The age at diagnosis was dichotomized into <65 and 65 years. Race was grouped as white and nonwhite. Comorbidities are reported in the NCDB on the basis of the Charlson/Deyo scoring system, and patients were categorized as having zero or any comorbid conditions. 18, 19 The insurance status was categorized as private insurance or any other type of insurance/no insurance. Treatment centers were divided into academic and nonacademic centers. The tumor location was dichotomized according to ICD-O-3 topography codes for the site of origin: head/neck (C25.0 and C25.7) or other (C25.1, C25.2, C25.3, C25.8, and C25.9). The clinical tumor stage was defined according to the 7th edition of the American Journal Committee on Cancer (AJCC) staging manual; if the group stage was not available, the definitive stage was computed by the combination of the clinical primary tumor (cT), the regional lymph node status (cN), and the presence or absence of distant metastasis (cM). 4, 20, 21 All patients included in this study received chemotherapy. The receipt of chemotherapy was defined as reported by the NCDB. Radiotherapy was coded according the Commission on Cancer facility oncology registry data manual. 22 In addition, for the purpose of this study, radiotherapy was categorized as no radiotherapy administrated, EBRT (external beam not otherwise specified, orthovoltage, cobalt-60 or cesium-137, photons alone or mixed energies, or 3-dimensional conformal radiotherapy), IMRT, or SBRT (SBRT not otherwise specified, Linac radiosurgery, or Gamma Knife). 23 EBRT refers to all patients for whom EBRT was reported as the first course of treatment (typically in the radiation oncologist's summary letter in the medical record); IMRT and SBRT were defined as external-beam techniques that were clearly defined in the patient record. In cases in which multiple radiotherapy modalities were used, radiotherapy was defined on the basis of the dominant modality stated in the medical record. The radiotherapy dose refers to radiotherapy delivered to the tumor during treatment and not to the biologically effective dose. For an estimation of the median radiotherapy dose, the cohort was capped at 64.0 Gy because higher values for EBRT, SBRT, or IMRT were not reported in the literature and were deemed to be clinically improbable. 24 Radiotherapy fractions were recorded as the number of sessions administered during the first course of treatment.
Statistical Analysis
Baseline characteristics are reported as frequencies, and continuous data are presented as medians and interquartile ranges (IQRs) unless otherwise indicated. Frequencies between 2 treatment groups were compared with the chisquare test. Three separate cohorts and propensity score models were created for the odds of receiving SBRT versus 1) chemotherapy alone, 2) EBRT, or 3) IMRT. The models were adjusted for age, sex, race, comorbidity, insurance, type of treatment center, tumor location, and clinical stage. For each cohort, we performed 1:1 matching without replacement on the basis of the propensity score with a caliper width equal to 0.2 of the standard deviation of the estimated probability of receiving treatment (with respect to SBRT); this 99% of the bias. 25 Three separate cohorts and propensity score models were created for the odds of receiving SBRT versus chemotherapy alone, EBRT, or IMRT with the following c statistics: 0.636 (calipers, 20.005053 to 0.005053), 0.678 (calipers, 20.006073 to 0.006073), and 0.672 (calipers, 20.014145 to 0.014145), respectively.
Survival was calculated from the date of diagnosis to the date of last follow-up or death. Survival analyses were performed with the Kaplan-Meier method and tested with log-rank statistics stratified by the treatment received.
Previous studies have demonstrated that multi-agent chemotherapy may provide a survival benefit over singleagent chemotherapy. 9, 26, 27 Therefore, sensitivity analyses were performed with the Kaplan-Meier method and the log-rank test to compare single-agent chemotherapy alone with multi-agent chemotherapy alone. In addition, survival after multi-agent chemotherapy alone was compared with survival after SBRT combined with multi-agent chemotherapy for patients with unresected nonmetastatic pancreatic cancer.
All analyses were performed with SAS 9.4 (SAS Institute, Cary, North Carolina) with a .05 level of significance.
RESULTS
Patient Characteristics
A total of 14,331 patients met the selection criteria. Chemotherapy alone was delivered to 5464 patients (38.1%); 6418 (44.8%), 322 (2.3%), and 2127 (14.8%) received chemotherapy combined with EBRT, SBRT, and IMRT, respectively. Patient and tumor characteristic are summarized in Tables 1 to 3. In the entire cohort, the majority of the patients were 65 years old or older at diagnosis ( Patients who received SBRT were more often white (P 5 .0191) and treated at academic centers (P < .0001) in comparison with patients who received chemotherapy alone. In addition, SBRT was associated with an age in comparison with EBRT (P 5 .0002) and IMRT (P 5 .0002) and with treatment at an academic facility in comparison with EBRT (P < .0001) and IMRT (P < .0001). However, after matching, the covariates were equally distributed, as shown in Tables 1 to 3 .
Treatment Characteristics
In the overall population, 7989 patients (55.8%) received single-agent chemotherapy, 5534 patients (38.6%) received multi-agent chemotherapy, and 808 patients (5.6%) had an unknown type and number of chemotherapeutic agents administered. Patients who received chemotherapy plus any additional radiotherapy were more likely to be treated with a single agent (59.8%) than those who received chemotherapy alone (49.2%); however, patients were more likely to be treated with a multi-agent regimen if they received chemotherapy alone (44.8%) versus chemotherapy plus radiation (34.8%; P < .0001). However, 5.6% of the total population (n 5 808) did not have a documented number of chemotherapeutic agents and/or type of chemotherapeutic regimen.
In the EBRT, SBRT, and IMRT cohorts, 5884 (91.7%), 288 (89.4%), and 2041 (96.0%) reported the radiation dose, respectively. In the overall cohort, the median radiation dose was 45.0 Gy (IQR, 45.0-50.4 Gy)
Original Article 
Survival Analyses
In the unmatched cohort, the median survival was 10.8 months for the overall cohort and 9.9, 10.9, 13.9, and 12.0 months for patients treated with chemotherapy alone, EBRT, SBRT, and IMRT, respectively. There was a significant difference in survival between the treatment groups in the unmatched cohort (log-rank P < .0001; Figs. 1 and 2A-C) .
After matching, patients who received SBRT had significantly improved median survival in comparison with patients who received chemotherapy alone (13.9 vs 10.2 months; log-rank P < .0001; Fig. 2D ). Furthermore, the median survival improved significantly after SBRT versus EBRT (13.9 vs 11.6 months; log-rank P 5 .0180; Fig. 2E ). However, SBRT did not significantly advance survival over IMRT after matching (13.9 vs 12.2 months; log-rank P 5 .0492; Fig. 2F ).
Sensitivity Analysis
In the sensitivity analysis, patients who received multiagent chemotherapy alone had significantly longer survival than patients who received single-agent chemotherapy alone (median overall survival, 11.4 vs 8.8 months; log-rank P < .0001; Fig. 3A) . However, survival after SBRT combined with multi-agent chemotherapy did not differ significantly from survival after multi-agent chemotherapy alone (median overall survival, 14.8 vs 12.9 months; log-rank P 5 .0953; Fig. 3B ).
DISCUSSION
This population-level analysis examined survival outcomes for patients with unresected pancreatic cancer after SBRT versus chemotherapy alone, EBRT, and IMRT. The results of this study suggest a survival advantage for SBRT versus chemotherapy alone (median survival, 13.9 vs 10.2 months; log-rank P < .0001) or chemotherapy plus EBRT (median survival, 13.9 vs 11.6 months; log-rank P 5 .0180) after for critical confounders. In addition, this study demonstrates improved survival after SBRT versus IMRT (median survival, 13.9 vs 12.2 months; log-rank P 5 .0492). These findings emphasize the potential of SBRT as a novel treatment approach for pancreatic cancer. [10] [11] [12] The role of radiotherapy for patients with unresected pancreatic cancer was established in the 1980s on the basis of the Gastrointestinal Tumor Study Group trials, which demonstrated a median survival of 7 months after chemotherapy versus 10 months after chemoradiotherapy. 28, 29 However, in the following decades, randomized controlled trials comparing chemotherapy with conventional fractionated EBRT have demonstrated mixed results. [5] [6] [7] [8] 28, 29 A phase 3 study from France that compared the 2 treatment options revealed increased toxicity and a significantly lower median survival of 9 months in its chemoradiotherapy arm versus 13 months after gemcitabine alone. However, the French phase 3 study was highly criticized because of its high-dose radiotherapy regimen. The latter may explain the low median survival in the EBRT arm of the trial, which diverged from the findings of our study. 5 On the contrary, a randomized trial coordinated by the Eastern Cooperative Oncology Group (ECOG) revealed significantly improved survival after EBRT versus chemotherapy alone (median overall survival, 11 vs 9 months). 30 The results of the ECOG trial are consistent with our findings. Furthermore, it should be noted that in the ECOG trial, patients in the chemotherapy arm received only gemcitabine, whereas in our study, 44.8% of the patients received multi-agent chemotherapy. Recently, large, multi-institutional randomized controlled trials have demonstrated that multi-agent chemotherapeutic regimens such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve survival in comparison with gemcitabine alone. 5, 9, 27, 28, 30 In accordance with recent trials, our study similarly reveals that multi-agent chemotherapy significantly improves survival in comparison with single-agent chemotherapy (median survival, 11.4 vs 8.8 months; log-rank P < .0001). 5, 9, 27, 28, 30 The recent phase 3 LAP 07 study compared gemcitabine-based induction chemotherapy with or without erlotinib and the same chemotherapy combined with chemoradiotherapy (54 Gy plus capecitabine) and found a modest improvement in local control after EBRT; unfortunately, the trial failed to demonstrate a survival advantage with EBRT (median overall survival, 15 vs 16 months). 6, 31 However, the LAP 07 trial was criticized for its protocol deviations, with some patients in the chemoradiotherapy arm not receiving radiation; this likely caused the impact of radiotherapy to be understated. 6 The median survival of patients treated with EBRT reported by the LAP 07 trial likely exceeded that found in our study on account of a selection bias because only patients with disease controlled after 4 months of induction chemotherapy were included. 6 In 2004, Koong et al 32 pioneered SBRT combined with gemcitabine for pancreatic cancer, and they demonstrated a median survival time of 8 months and a 100% local control rate. Subsequently, separate trials by the same research group using single-fraction SBRT reported similar results with a median survival of 11 to 12 months. 33, 34 However, our study demonstrates slightly longer median overall survival after SBRT, and this could possibly be explained by the common use of hypofractionated SBRT (median number of fractions, 3). Taking into consideration the high toxicity related to single-fraction SBRT, many succeeding studies have evaluated the use of hypofractionated SBRT instead of single-fraction SBRT. Rwigema et al 13 reported on 71 patients treated with SBRT for locally unresectable and metastatic disease. Their study demonstrated that hypofractionated SBRT is feasible with minimal toxicity and without delays in adjuvant systemic treatment. In addition, 81.3% of their patients reported complete pain Recent studies have demonstrated more favorable outcomes after SBRT treatment. A retrospective series by Gurka et al, 35 including 38 patients with locally advanced, borderline resectable, and medically inoperable pancreatic cancer treated with SBRT and gemcitabine or folinic acid, fluorouracil, and oxaliplatin (modified FOLFOX), revealed a median overall survival of 14.3 months. 35 A subsequent study by Moningi et al 36 evaluating patients with borderline resectable and locally advanced pancreatic cancer showed similar results with a median survival of 13.9 months. Similarly, a multi-institutional phase 2 study of 49 patients with locally advanced pancreatic cancer treated with gemcitabine followed by SBRT also demonstrated a median overall survival of 13.9 months. These results are in agreement with the findings of our study.
Mahadevan et al reported a median overall survival of 20 months for 47 patients who received gemcitabine followed by SBRT. However, only patients with no evidence of metastatic progression after 2 cycles of gemcitabine were included and treated with SBRT. These results are similar to our findings and may be explained by the careful selection of patients who benefit the most from local therapy with SBRT.
SBRT is also a feasible treatment option for patients with resected pancreatic cancer. A study at the Lee Moffitt Cancer Center revealed a median overall survival of 34 months after neoadjuvant FOLFIRINOX and SBRT with a resection rate of 38% for patients with locally advanced and borderline resectable cancer. Likewise, Rwigema et al reported a promising median survival of 27 months after resection followed by adjuvant SBRT, and the initiation of chemotherapy was not delayed because of the short treatment course of SBRT.
In addition to SBRT, other new radiation modalities have been used in the treatment of locally advanced pancreatic cancer, including IMRT. This approach is expected to provide more conformal dose delivery in comparison with conventional 3-dimensional conformal radiotherapy and consequently permit a higher radiation dose and reduce treatment-related toxicity. Median survival times for patients with unresected pancreatic cancer receiving IMRT range from 12 to 14 months. Lin et al compared SBRT with IMRT for locally advanced patients and showed an advantage for SBRT in achieving local control. Nevertheless, in agreement with our findings, no significant difference in overall survival between the 2 radiotherapy techniques was found.
Because of the conflicting results surrounding the benefit of chemoradiotherapy in locally advanced pancreatic cancer and the small institutional trials, a nationwide study using data from the Surveillance, Epidemiology, and End Results Program was performed. This study demonstrated that radiotherapy was associated with improved survival, even after propensity score matching: the median survival. However, this study did not differentiate between the various radiotherapy modalities and included patients who did not receive any chemotherapy in the control group; this explains the inferior median survival for patients who did not receive radiotherapy.
Our study is limited by its retrospective nature and the use of a large nationwide registry, which may be limited by coding errors. Several important prognostic variables were not reported by the NCDB or were missing for a majority of the patients, including the Karnofsky performance status, carbohydrate antigen 19-9 levels, and surgical resectability. Consequently, the current study included patients who did not undergo surgery even if they had potentially resectable tumors. Furthermore, comparative effectiveness studies are often hampered by a selection bias, with patients who received SBRT likely chosen carefully by the treating physician. To account for the potential selection bias, we used matching to balance patient and tumor characteristics. However, unknown confounders for which the propensity score matching process could not completely account may have influenced treatment allocation. Moreover, the group of patients who received SBRT was still small in comparison with the other groups classified, and this reduced the power and generalizability of this study. In addition, the NCDB provides no data on key oncologic outcomes, including progression-free survival, treatment-related toxicity, and quality of life. This study was also unable to account for the specific SBRT regimens or the impact of volumetric-modulated arc therapy. Widespread implementation of SBRT remains to be achieved. Consequently, these findings are limited to early adopters. Furthermore, Commission on Cancerapproved hospitals are larger, more frequently accredited by major oversight agencies, and exhibit a higher degree of oncology-related specialization. Hence, this study may also not be entirely representative of all hospitals in the United States. In addition, the median biologically equivalent radiation dose in the SBRT group was lower in comparison with the EBRT and IMRT groups. Consequently, this study may underestimate the survival benefit of SBRT. However, dose escalation of SBRT for pancreatic cancer is limited by critical surrounding structures, especially the duodenum.
Despite its limitations, using propensity scorematched models, the current study employed a nationwide cohort to investigate the survival impact of SBRT in comparison with both traditional and novel therapeutic approaches for unresected pancreatic cancer. The NCDB allows the analysis of quality-assured data for a large cohort of patients from different institutions. In addition, the NCDB is an improvement on other nationwide data sets because it includes the radiation dose, fractionation, treatment modality, and receipt of chemotherapy. The median survival times for chemotherapy alone, EBRT, IMRT, and SBRT are comparable to those of historical series. Moreover, the findings regarding the dose and number of fractions for EBRT, IMRT, and SBRT correspond with the appropriate guidelines. To control for an immortality bias, the cohort was restricted to patients who lived at least 3 months beyond the time of the initial diagnosis. 17 Furthermore, to ensure curative intent, all patients with metastatic disease were excluded. Consequently, the results of this study likely provide an appropriate reflection of the comparative effectiveness of this novel treatment approach.
Although nonrandomized, to the best of our knowledge, this study is the first to demonstrate the superiority of SBRT over chemotherapy alone or in combination with conventionally fractionated EBRT for the survival of patients with unresected nonmetastatic pancreatic cancer. The use of SBRT resulted in a promising median survival of 13.9 months, which was 3 months longer than survival with traditional approaches. Previous studies have demonstrated that SBRT is an attractive therapeutic option because of its short duration, safety, and high rate of local control. Our data, in conjunction with the published literature, support the expanded implementation of SBRT for patients with unresected pancreatic cancer and highlight the need for future trials.
Future trials should evaluate the outcomes of SBRT combined with multi-agent chemotherapy versus multi-agent chemotherapy alone or in combination with conventionally fractionated EBRT. In addition, future trials should also include potentially resectable patients and examine toxicity and quality-of-life measures.
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